Additive effect of inhaled corticosteroid (ICS) on patients with COPD receiving long acting muscarinic antagonist (LAMA)/long acting beta2 agonist (LABA) single center, real world study
Not Applicable
Completed
- Conditions
- COPD
- Registration Number
- JPRN-UMIN000037192
- Lead Sponsor
- Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School
- Brief Summary
not analysed, yet.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Male
- Target Recruitment
- 37
Inclusion Criteria
Not provided
Exclusion Criteria
Excluded from the study were those with a documented history of asthma or a bronchodilator response (BDR) to 400g salbutamol shown as a FEV1 change of 200ml or more than 200 mL and those confirmed to have received LAMA, LABA or ICS other than the study drug or their combination.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method